Inflammation and Respiratory Diseases

Interstitial lung diseases (ILD) are a group of parenchymal lung disorders characterized by different clinical patterns that cause pulmonary fibrosis. A number of reports are showing that the current treatment strategy remains ineffective for a considerable proportion of patients including chronic Asthma patients. Biologic treatments have emerged for several immune and respiratory disorders therapeutic tool for cardiovascular disease patients.

The current Biologic therapies are to represent an alternative medication in sarcoidosis cases. The first line of immunomodulatory agents are to include corticosteroids, methotrexate, azathioprine, leflunomide and mycophenolate mofetil. Recent reports have shown, TNFα- inhibitors are preferred for patients with persistent disease combined with corticosteroids and other second-line immunomodulatory compounds treatment as in cases of life-threatening disease. However, these strategies need thorough pre-treatment evaluation and multidisciplinary approaches that highlight the importance of cytokine testing.

Canakinumab, a human monoclonal antibody against IL-1b, has entered the pipeline of clinical trials for sarcoidosis. The list of asthma medications have included IL-5 inhibitor, Leukotriene Receptor Antagonists (LTRA) in addition to the conventional oral corticosteroids.

Lung inflammation involves the activation of inflammatory cells, such as macrophages, lymphocytes, neutrophils, and eosinophils, which are a source of different kinds of inflammatory mediators such as histamine, tumor necrosis factor (TNF-𝛼), interleukins, IL-1𝛽, IL-4, IL-5, IL-6, IL-17, IL-23, prostaglandins and leukotrienes. Several studies have observed significant elevation of cytokine and chemokine levels including IL-6, IL-8 in patients with ILD that confirms the disease outcome.

Ask your doctor about the Biomarker testing. The biomarker's testing as preventive medicine: a new approach to stay healthy. Biomarkers are useful for:

• Disease prevention and screening
• Monitoring disease progress and response to treatment
• Drug selection

Our laboratory services are for informational purposes only. It is not the intention of Canada Metabolic Inflammation Diagnostics Inc. to provide specific medical advice but rather to provide users with information to better understand their health. Specific medical advice including diagnosis and treatment will not be provided. Always seek the advice of a trained health professional for medical adivce, diagnosis or treatment.